Skin cancer vaccine FDA approved by June 30, 2027?

As of November 8, 2026, Polymarket prices “Skin cancer vaccine FDA approved by June 30, 2027?” at 16% YES with $51K traded. No tracked wallet holds a position on this market, so there is no verdict.

Prediction markets put the probability at 16%: Skin cancer vaccine FDA approved by June 30, 2027. Currently, markets see this as unlikely (16% YES).

What’s Happening

The question of whether a skin cancer vaccine will secure FDA approval by June 30, 2027 has gained traction following a series of clinical and regulatory developments involving Moderna and Merck & Co. In April 2026, a melanoma vaccine received FDA Fast Track designation, a status designed to expedite review of therapies addressing serious conditions with unmet medical need. The designation does not guarantee approval but can shorten the review timeline and allow for more frequent communication with regulators. Fast Track status is typically granted on the basis of preliminary clinical evidence suggesting meaningful improvement over existing options. [CancerNetwork, Apr 28]

The clinical momentum continued into the summer. In August 2026, Moderna and Merck reported what was described as a "landmark" result from their mRNA-based melanoma cancer vaccine program, restoring investor confidence in Moderna's oncology pipeline after a period of uncertainty. The company has signaled it intends to direct cash from its respiratory franchise into oncology and rare disease programs, and has indicated that study results for the skin cancer vaccine candidate could materialize in the near term. Whether a skin cancer vaccine FDA approved by June 30, 2027 is achievable depends heavily on whether those results support a full biologics license application rather than an accelerated pathway. [BioPharma Dive, Aug 20]

Regulatory precedent for mRNA platforms has also shifted. On August 5, 2026, the FDA approved mFLUSIVA, Moderna's mRNA influenza vaccine, for adults aged 50 and older — the first mRNA flu vaccine available in the U.S. — receiving traditional approval for ages 50 to 64 and accelerated approval for those 65 and older. The approval demonstrates the agency's willingness to clear mRNA-based products, though cancer vaccines face distinct evidentiary hurdles, including endpoint selection and trial duration. The timing of any skin cancer vaccine FDA approval decision remains contingent on Phase 3 data readouts and submission schedules not yet publicly confirmed. [NCOA, Sep 24]

Traded on Polymarket — $51K Volume